Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

6.09USD
20 Jun 2018
Change (% chg)

$0.12 (+2.01%)
Prev Close
$5.97
Open
$5.99
Day's High
$6.16
Day's Low
$5.97
Volume
232,941
Avg. Vol
234,448
52-wk High
$6.67
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

Great Point Partners Says Delivered Letter To Biocryst Pharma
2:21am IST 

June 20 (Reuters) - BioCryst Pharmaceuticals Inc ::GREAT POINT PARTNERS SAYS DELIVERED LETTER TO BIOCRYST PHARMACEUTICALS REAFFIRMING ITS OBJECTIONS TO PROPOSED MERGER OF BIOCRYST & IDERA PHARMACEUTICALS.  Full Article

Biocryst Urges Stockholders To Vote "For" Merger Transaction With Idera
Tuesday, 5 Jun 2018 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC SAYS URGE STOCKHOLDERS TO VOTE "FOR" MERGER TRANSACTION WITH IDERA PHARMACEUTICALS.  Full Article

Biocryst Pharmaceuticals Q1 Loss Per Share $0.26
Tuesday, 8 May 2018 

May 8 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.26.Q1 REVENUE $4.0 MILLION VERSUS $9.4 MILLION.Q1 REVENUE VIEW $6 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.BIOCRYST CONTINUES TO EXPECT ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION.  Full Article

BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza
Tuesday, 1 May 2018 

May 1 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA.  Full Article

Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES.IDERA PHARMACEUTICALS INC - ‍MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.IDERA PHARMACEUTICALS INC - ROBERT INGRAM TO BE CHAIRMAN OF BOARD, VINCENT MILANO TO BE CEO OF COMBINED COMPANY.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF BIOCRYST COMMON STOCK WILL BE EXCHANGED FOR 0.50 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF IDERA COMMON STOCK WILL BE EXCHANGED FOR 0.20 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - ‍SIGNIFICANT STOCKHOLDER OF CO, BIOCRYST AGREED TO ENTER VOTING AND SUPPORT AGREEMENT AND HAS AGREED TO VOTE IN FAVOR OF DEAL​.IDERA PHARMACEUTICALS INC - AFTER DEAL BIOCRYST STOCKHOLDERS WILL OWN 51.6 PERCENT OF STOCK OF COMBINED COMPANY, CO'S STOCKHOLDERS TO OWN 48.4 PERCENT.IDERA PHARMACEUTICALS - COMBINED COMPANY, WHICH WILL BE RENAMED POST-CLOSING, WILL BE HEADQUARTERED AT CURRENT IDERA HEADQUARTERS.IDERA PHARMACEUTICALS INC - STOCK ISSUANCE IN MERGER IS EXPECTED TO BE TAX-FREE TO STOCKHOLDERS.  Full Article

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article

Biocryst Pharmaceuticals prices public offering of common stock
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst Pharmaceuticals prices public offering of common stock.Pricing of underwritten public offering of 15.5 million shares of common stock, offered at a price to public of $5.15 per share.  Full Article

D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11
Tuesday, 23 Aug 2016 

Biocryst Pharmaceuticals Inc :D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing.  Full Article

Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals
Thursday, 18 Aug 2016 

Biocryst Pharmaceuticals Inc : Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing .Baker Bros' Felix Baker's stake of about 11.1 million shares in Biocryst Pharmaceuticals includes 75,000 shares of co's common stock underlying options.  Full Article